NO995843L - Farmasoeytisk preparat omfattende vWF-propeptid - Google Patents

Farmasoeytisk preparat omfattende vWF-propeptid

Info

Publication number
NO995843L
NO995843L NO995843A NO995843A NO995843L NO 995843 L NO995843 L NO 995843L NO 995843 A NO995843 A NO 995843A NO 995843 A NO995843 A NO 995843A NO 995843 L NO995843 L NO 995843L
Authority
NO
Norway
Prior art keywords
pharmaceutical preparation
vwf propeptide
vwf
propeptide
preparation
Prior art date
Application number
NO995843A
Other languages
English (en)
Other versions
NO995843D0 (no
NO324064B1 (no
Inventor
Hans-Peter Schwarz
Katalin Varadi
Peter Turecek
Hendrik Coenraad Hemker
Suzette Lucette Beguin
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of NO995843D0 publication Critical patent/NO995843D0/no
Publication of NO995843L publication Critical patent/NO995843L/no
Publication of NO324064B1 publication Critical patent/NO324064B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19995843A 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav NO324064B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE

Publications (3)

Publication Number Publication Date
NO995843D0 NO995843D0 (no) 1999-11-29
NO995843L true NO995843L (no) 2000-01-27
NO324064B1 NO324064B1 (no) 2007-08-06

Family

ID=3502803

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995843A NO324064B1 (no) 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav

Country Status (10)

Country Link
US (2) US7005502B1 (no)
EP (1) EP0977584B1 (no)
JP (1) JP4335978B2 (no)
AT (2) AT405485B (no)
AU (1) AU744643B2 (no)
CA (1) CA2288737A1 (no)
DE (1) DE69802918T2 (no)
ES (1) ES2168766T3 (no)
NO (1) NO324064B1 (no)
WO (1) WO1998053848A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430578T1 (de) * 1999-12-24 2009-05-15 Chemo Sero Therapeut Res Inst Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2007126808A1 (en) 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
NZ592905A (en) * 2008-10-27 2012-11-30 Baxter Int Models of thrombotic thrombocytopenic purpura and methods of use thereof
MX2012002129A (es) 2009-08-20 2012-06-08 Baxter Int Purificacion del factor de von willebrand (vwf) para remocion incrementada de virus envueltos sin lipido.
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL2017452A (en) 2015-10-02 2017-04-11 Asml Netherlands Bv Metrology method and apparatus, computer program and lithographic system
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
CA3094644A1 (en) 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CA3169996A1 (en) 2020-02-04 2021-08-12 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
EP0674531A1 (de) 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) * 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase

Also Published As

Publication number Publication date
EP0977584B1 (en) 2001-12-12
CA2288737A1 (en) 1998-12-03
EP0977584A1 (en) 2000-02-09
AU744643B2 (en) 2002-02-28
NO995843D0 (no) 1999-11-29
JP2001527579A (ja) 2001-12-25
JP4335978B2 (ja) 2009-09-30
US20060003921A1 (en) 2006-01-05
WO1998053848A1 (en) 1998-12-03
US7557188B2 (en) 2009-07-07
DE69802918D1 (de) 2002-01-24
AT405485B (de) 1999-08-25
DE69802918T2 (de) 2003-04-10
ATE210455T1 (de) 2001-12-15
US7005502B1 (en) 2006-02-28
ES2168766T3 (es) 2002-06-16
ATA91797A (de) 1999-01-15
NO324064B1 (no) 2007-08-06
AU7915698A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
NO995843D0 (no) Farmasöytisk preparat omfattende vWF-propeptid
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
NO179531C (no) Fremgangsmåte for brönnbehandling
PT865294E (pt) Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob
ATE239474T1 (de) Verwendung von levobupivacain
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69736180D1 (de) Behandlung von manischen erkrankungen
BR0012921A (pt) Compostos calcilìticos
EA199800535A1 (ru) Способ лечения боли
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
NO995132L (no) Fremgangsmåte for reduksjon av fibrinogen
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATA159597A (de) Präparat zur behandlung von blutgerinnungsstörungen
EA199800818A1 (ru) Способ лечения бессонницы
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAXALTA INCORPORATED, CH

MK1K Patent expired